Remote Heart Rhythm Monitoring After Transcatheter Aortic Valve Replacement
Tests 30 days of remote heart rhythm monitoring in adults after aortic valve replacement.
Plain-language title generated from the registry record
Registry title: Remote ECG Monitoring Post TAVI
Key facts
- Where
- Turin, ItalySee the site
Where in Italy
- Division of Cardiology, Departement of Medical Science University of Turin, Città della Salute e Della ScienzaTurin, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Silesia
- Trial code
- NCT07521800
- Record updated
- 13 April 2026
- Original description
The DRAGON TAVI study is a multicenter, prospective, open, randomised trial, which will enrol 250 patients, randomized 1:1 to the study group (continuous 30-day ECG monitoring with visits triggered by ECG findings) and standard care (ie. control group, which will receive the standard post op 24-48h ECG monitoring and a regular follow-up visit with standard ECG within 30 days). The duration of the study is 12 months ± 1 month.Read full original descriptionShow less
Remote ECG Monitoring as a Diagnostic Tool for Therapeutic Strategies After Transcatheter Aortic Valve Replacement: Rationale and Design of the DRAGON-TAVI Trial.
The DRAGON TAVI study is a multicenter, prospective, open, randomised trial, which will enrol 250 patients, randomized 1:1 to the study group (continuous 30-day ECG monitoring with visits triggered by ECG findings) and standard care (ie. control group, which will receive the standard post op 24-48h ECG monitoring and a regular follow-up visit with standard ECG within 30 days). The duration of the study is 12 months ± 1 month.
Inclusion: Patient age over 18 years old; Severe aortic stenosis; Moderate or high cardiovascular risk based on current ESC Guidelines "Heart Team" qualification for TAVI; Written informed consent of the patient for participation in the study.
Exclusion: Previously known conduction disturbances**; Ischaemic stroke, TIA, MI or heart surgery within 1 month before TAVI qualification; Chronic immunosuppressive therapy; History of atrial fibrillation or atrial flutter; Haemorrhagic stroke within 1 year before TAVI qualification; Comorbidities (e.g. drug addiction, alcohol abuse, emotional/mental disorders) which do not allow safe participation in the study; Presence of: pacemaker, CRT-P, ICD, CRT-D before or after TAVI.